期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 129, 期 8, 页码 3171-3184出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI125538
关键词
-
资金
- Marianne Barrie Philanthropic Fund
- Canadian Institutes of Health Research [RN332805]
- Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation
- Dutch Federation of University Medical Centers
- Netherlands Organisation for Health Research and Development
- Royal Netherlands Academy of Sciences [CVON-PREDICT 2012-10]
- Netherlands Cardiovascular Research Initiative - Dutch Heart Foundation [CVON2012-10 PREDICT CVON2018-30 PREDICT2, CVON2015-12 eDETECT]
- Netherlands Organization for Scientific Research (NWO) [040.11.586]
- Fondation Leducq [16 CVD 02]
- Dr. Francis P. Chiramonte Private Foundation
- Leyla Erkan Family Fund for ARVD Research
- Robin Shah ARVD Fund at Johns Hopkins
- Bogle Foundation
- Healing Hearts Foundation
- Campanella Family
- Patrick J. Harrison Family
- Peter French Memorial Foundation
- Wilmerding Endowments
- NIH [HL135754, HL134824, HL139348, HL135096, HL114383, HL114893, HL137331, HL137325, 2UM1HG006542, UL1 TR 001079]
- Ohio State Frick Center
- JB Project
Arrhythmogenic cardiomyopathy (ACM) is an inherited arrhythmia syndrome characterized by severe structural and electrical cardiac phenotypes, including myocardial fibrofatty replacement and sudden cardiac death. Clinical management of ACM is largely palliative, owing to an absence of therapies that target its underlying pathophysiology, which stems partially from our limited insight into the condition. Following identification of deceased ACM probands possessing ANK2 rare variants and evidence of ankyrin-B loss of function on cardiac tissue analysis, an ANK2 mouse model was found to develop dramatic structural abnormalities reflective of human ACM, including biventricular dilation, reduced ejection fraction, cardiac fibrosis, and premature death. Desmosomal structure and function appeared preserved in diseased human and murine specimens in the presence of markedly abnormal beta-catenin expression and patterning, leading to identification of a previously unknown interaction between ankyrin-B and beta-catenin. A pharmacological activator of the WNT/beta-catenin pathway, SB-216763, successfully prevented and partially reversed the murine ACM phenotypes. Our findings introduce what we believe to be a new pathway for ACM, a role of ankyrin-B in cardiac structure and signaling, a molecular link between ankyrin-B and beta-catenin, and evidence for targeted activation of the WNT/beta-catenin pathway as a potential treatment for this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据